Interventional, Open-label, Interaction Study Investigating the Effects of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics and Safety and Tolerability of Lu AF11167 in Healthy Young Subjects

Trial Profile

Interventional, Open-label, Interaction Study Investigating the Effects of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics and Safety and Tolerability of Lu AF11167 in Healthy Young Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Lu AF11167 (Primary) ; Itraconazole
  • Indications Neurodegenerative disorders; Psychotic disorders
  • Focus Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 18 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 25 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2014, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top